the present invention relates to aqueous solutions useful as pharmaceutical compositions of posaconazole for intravenous administration . these compositions include a solubilizing agent , such as a modified β - cyclodextrin in an acidified solution , which can also include a chelating agent such as disodium edetate . in clinical trials , a 200 mg posaconazole dose of the selected composition was found to achieve acceptable pharmacokinetic properties .